SPRO (Spero Therapeutics) Institutional Ownership: 39.99% (As of Jun. 30, 2026)


SPRO Spero Therapeutics Inc SPRO
55 GF Score
Price $2.27
GF Value $1.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics Institutional Ownership?

Spero Therapeutics SPRO 55 Institutional Ownership is 39.99% as of Jun. 30, 2026. GuruFocus rates SPRO with a GF Score™ of 55/100 and a GF Value™ of $1.06 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Spero Therapeutics's institutional ownership is 39.99%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Spero Therapeutics's Insider Ownership is 10.66%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Spero Therapeutics's Float Percentage Of Total Shares Outstanding is 82.86%.

Spero Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Spero Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spero Therapeutics Institutional Ownership Chart

Spero Therapeutics Historical Data

The historical data trend for Spero Therapeutics can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31
Institutional Ownership 7.94 8.39 8.19 8.50 8.15 8.12 7.60 6.62 6.63 6.70
SPRO
55GF Score
Spero Therapeutics Inc SPRO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spero Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 39.99% mean?
Spero Therapeutics (SPRO) has a Institutional Ownership of 39.99% as of Jun. 30, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Spero Therapeutics and its competitors.
Is Spero Therapeutics' Institutional Ownership too high?
Spero Therapeutics' current Institutional Ownership is 39.99%. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Institutional Ownership compare to VXRT and ADCT?
Spero Therapeutics' Institutional Ownership of 39.99% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current Institutional Ownership is 39.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.06, compared to a current price of $2.27 — trading 114.2% above its estimated fair value. The current Institutional Ownership is 39.99%. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current Institutional Ownership is 39.99% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.27 is trading 114.2% above its estimated GF Value™ of $1.06. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

  • Institutional Ownership: 39.99%
  • GF Value™: $1.06 vs. price of $2.27 (114.2% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Other Exchanges 2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score

Get the complete analysis for SPRO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.27
Price
$1.06
GF Value